Nanobiotix S.A. (EPA:NANO)
France · Delayed Price · Currency is EUR 22.86
-2.54 (-10.00%)
Oct 2, 2026, 5:35 PM CET
Nanobiotix Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8.36 | 29.64 | -11.61 | 30.06 | - | 0.01 |
Other Revenue | 3.15 | 2.95 | 4.42 | 6.15 | 4.78 | 2.64 |
| 11.51 | 32.59 | -7.19 | 36.21 | 4.78 | 2.65 | |
Revenue Growth | 13.27% | - | - | 658.10% | 80.43% | 13.85% |
Gross Profit | 11.51 | 32.59 | -7.19 | 36.21 | 4.78 | 2.65 |
Selling, General & Admin | 19.82 | 20.36 | 20.53 | 22.05 | 17.86 | 19.43 |
Research & Development | 21.31 | 23.12 | 40.54 | 38.4 | 32.64 | 30.38 |
Operating Expenses | 41.13 | 43.48 | 61.07 | 60.45 | 50.49 | 49.81 |
Operating Income | -29.62 | -10.88 | -68.26 | -24.24 | -45.72 | -47.17 |
Interest Expense | -20.7 | -10.4 | -8.09 | -7.98 | -5.84 | -0.67 |
Interest & Investment Income | 1.06 | 0.99 | 2.63 | 1.22 | 0.26 | - |
Currency Exchange Gain (Loss) | -0.97 | -3.23 | 2.99 | -2.09 | 2.11 | 6.24 |
Other Non Operating Income (Expenses) | -0.02 | -0.02 | 0 | 0 | 0 | 0.01 |
EBT Excluding Unusual Items | -50.25 | -23.54 | -70.73 | -33.09 | -49.19 | -41.58 |
Gain (Loss) on Sale of Investments | - | - | - | -4.23 | - | - |
Other Unusual Items | -2.61 | -0.42 | 2.7 | -2.26 | -7.84 | -5.41 |
Pretax Income | -52.85 | -23.96 | -68.03 | -39.58 | -57.03 | -47 |
Income Tax Expense | 0.01 | 0 | 0.1 | 0.12 | 0.01 | 0.01 |
Net Income | -52.87 | -23.96 | -68.13 | -39.7 | -57.04 | -47 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.06 |
Net Income to Common | -52.87 | -23.96 | -68.13 | -39.7 | -57.04 | -47.06 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 49 | 48 | 47 | 37 | 35 | 35 |
Shares Outstanding (Diluted) | 49 | 48 | 47 | 37 | 35 | 35 |
Shares Change | 2.40% | 1.17% | 27.99% | 5.96% | 0.34% | 42.43% |
EPS (Basic) | -1.09 | -0.50 | -1.44 | -1.08 | -1.64 | -1.35 |
EPS (Diluted) | -1.09 | -0.50 | -1.44 | -1.08 | -1.64 | -1.35 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -35.2 | -33.96 | -20.4 | -12.8 | -37.2 | -30.1 |
Free Cash Flow Per Share | -0.72 | -0.71 | -0.43 | -0.35 | -1.07 | -0.87 |
Gross Margin | 100.00% | 100.00% | - | 100.00% | 100.00% | 100.00% |
Operating Margin | -257.43% | -33.39% | - | -66.94% | -957.22% | -1781.83% |
Profit Margin | -459.46% | -73.52% | - | -109.65% | -1194.33% | -1777.97% |
Free Cash Flow Margin | -305.94% | -104.19% | - | -35.36% | -778.79% | -1137.14% |
EBITDA | -29.79 | -10.49 | -67.67 | -22.73 | -44.22 | -45.61 |
EBITDA Margin | -258.87% | -32.18% | - | -62.76% | - | - |
D&A For EBITDA | -0.17 | 0.39 | 0.59 | 1.51 | 1.5 | 1.56 |
EBIT | -29.62 | -10.88 | -68.26 | -24.24 | -45.72 | -47.17 |
EBIT Margin | -257.43% | -33.39% | - | -66.94% | - | - |
Revenue as Reported | 11.51 | 32.59 | -7.19 | 36.21 | 4.78 | 2.65 |